Anthrax Vaccine - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The anthrax vaccine market size is expected to grow from USD 5.98 billion in 2025 to USD 6.39 billion in 2026 and is forecast to reach USD 8.88 billion by 2031 at 6.84% CAGR over 2026-2031. This report is Segmented by Vaccine Type (Cell-Free Anthrax Vaccine Adsorbed (AVA), Adjuvanted Anthrax Vaccine and More), by Application Type (Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis), by Distribution Channel (Direct Government Procurement, Hospital & Clinic Pharmacies and More), and Geography (North America, Europe, Asia Pacific and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Anthrax Vaccine Market Trends and Insights

Government Biodefense Stockpiling Budgets Increasing Post-COVID

National budgets reclassified anthrax countermeasures as core security assets. The U.S. Strategic National Stockpile expanded multi-year contracts, including a USD 250 million modification covering CYFENDUS, highlighting lessons from pandemic supply bottlenecks. Canada’s Health Emergency Readiness Canada initiative adds regional alignment with domestic manufacturing capacity. Defense Threat Reduction Agency grants of USD 26.3 million sustain R&D pipelines, ensuring that the anthrax vaccine market remains integrated into broader chemical-biological defense funding.

Mandatory Vaccination Programs for Military & High-Risk Lab Personnel

Compulsory protocols broaden beyond troops to laboratory and emergency response staff, reinforcing the anthrax vaccine market in established buying centers. The CDC’s 2023 guideline update enlarges the eligible workforce, while an FDA-approved five-dose schedule improves adherence logistics. NATO interoperability standards likewise push adoption across allied forces.

Adverse-Event Profile & Litigation Risk Limits Civilian Uptake

Injection-site reactions and past legal disputes dampen broad-based demand. Civilian insurers seldom reimburse preventive doses, and no pediatric indication exists, narrowing the anthrax vaccine market beyond government channels.

Other drivers and restraints analyzed in the detailed report include:

• Regulatory Approvals of Next-Generation Vaccines (e.g., CYFENDUS)
• Rising Geopolitical Bioterrorism Threat Perception Globally
• Dependence on a Single Dominant Supplier Creates Supply Risk

Segment Analysis

Cell-free formulations commanded 48.12% anthrax vaccine market share in 2025 as longstanding familiarity drove procurement. Adjuvanted AV7909, led by CYFENDUS, grows at 8.01% CAGR on faster seroconversion that meets emergency timelines. Manufacturing strategies pivot toward recombinant antigens, evidenced by GC-1109’s licensure, easing biosafety constraints inherent in culture-based production. Patent filings for thermostable spray-dried doses aim to remove cold-chain costs and widen reach in low-resource markets.

A future pipeline that includes mRNA and viral-vector concepts remains preclinical but could disrupt the anthrax vaccine industry if single-dose efficacy targets are met. Cross-sector lessons from COVID-19 have validated adjuvant dose-sparing frameworks, likely accelerating platform diversification.

Military & Defense held 55.02% of the anthrax vaccine market size in 2025, anchored by locked-in contracts and deployment protocols. Civilian agencies expand at 8.32% CAGR, propelled by CDC guidance encompassing lab workers and first responders. Veterinary and One Health programs grow where endemic livestock outbreaks occur, linking animal health budgets to human countermeasure funding.

International collaborations, such as India’s BioThrax partnership with Biological E., bring supply closer to regional civilian buyers, easing import reliance and raising baseline demand across South Asia investors.emergentbiosolutions.com. Research institutions also raise call-off volumes to satisfy biosafety clearances for anthrax-related experimentation.

Complete Report Scope:

• By Vaccine Type (Value)
  • Cell-free Anthrax Vaccine Adsorbed (AVA)
  • Adjuvanted Anthrax Vaccine (AV7909/CYFENDUS)
  • Recombinant Protective Antigen Vaccine
  • Others
• By End User (Value)
  • Military & Defense
  • Government Civilian Agencies
  • Healthcare Workers & First Responders
  • Veterinary Sector
  • General Population High-risk Travelers
• By Application (Value)
  • Pre-Exposure Prophylaxis
  • Post-Exposure Prophylaxis
• By Distribution Channel (Value)
  • Direct Government Procurement
  • Hospital & Clinic Pharmacies
  • Direct Order Suppliers
• By Geography (Value)
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa

Geography Analysis

North America retained 58.05% anthrax vaccine market share in 2025, supported by the Strategic National Stockpile’s rolling replenishments and consistent FDA approvals. A USD 2 billion domestic manufacturing drive under the BioMaP-Consortium strengthens regional self-reliance, while Canada’s HERC program aligns cross-border capacity.

Asia-Pacific posts the fastest CAGR at 9.35% to 2031. South Korea’s GC-1109 breakthrough and India’s BioThrax approval embed local production, diminishing sole dependence on U.S. supply and amplifying regional orders. Thailand’s 2025 anthrax outbreak response highlighted the urgency for wider livestock and human vaccine availability, prompting ASEAN regulators to discuss harmonized fast-track pathways.

Europe sustains moderate growth as the EU’s Health Technology Assessment Regulation targets synchronized member-state decisions on critical vaccines. Recent African outbreaks drive donor-funded procurements, although constrained budgets limit immediate volume. Latin American interest rises slowly, awaiting structured financing mechanisms that could tap into regional development banks.

List of Companies Covered in this Report:

• Emergent Bio Solutions
• Altimmune (Pharmathene Inc.)
• Proton Biopharma
• Colondo Serum Company
• Merck
• Bayer
• Zoetis
• Indian Immunologicals
• Agrovet
• Biogenesis Bago
• Tiankang
• GC Biopharma
• Sparhawk Laboratories
• Elusys Therapeutics

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support